Sichuan Hebang Biotechnology Corporation Limited
SSE:603077.SS
1.69 (CNY) • At close April 29, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 8,824.108 | 13,038.948 | 9,867.109 | 5,260.766 | 5,969.101 | 6,009.019 | 4,737.646 | 3,462.552 | 2,862.644 | 2,185.699 | 1,602.664 | 1,737.771 | 1,899.97 | 1,432.872 | 844.373 |
| Cost of Revenue
| 6,823.381 | 7,451.315 | 5,729.647 | 4,271.965 | 4,609.173 | 4,680.835 | 3,534.851 | 2,636.183 | 2,234.891 | 1,727.382 | 1,295.47 | 1,085.211 | 1,092.607 | 973.431 | 645.131 |
| Gross Profit
| 2,000.727 | 5,587.633 | 4,137.463 | 988.801 | 1,359.928 | 1,328.184 | 1,202.795 | 826.369 | 627.753 | 458.316 | 307.194 | 652.56 | 807.363 | 459.441 | 199.242 |
| Gross Profit Ratio
| 0.227 | 0.429 | 0.419 | 0.188 | 0.228 | 0.221 | 0.254 | 0.239 | 0.219 | 0.21 | 0.192 | 0.376 | 0.425 | 0.321 | 0.236 |
| Reseach & Development Expenses
| 47.347 | 67.934 | 33.313 | 39.677 | 38.3 | 31.144 | 34.76 | 25.059 | 3.809 | 0 | 0 | 12.454 | 0 | 0 | 0 |
| General & Administrative Expenses
| 93.298 | 73.525 | 65.65 | 81.961 | 59.694 | 84.508 | 73.962 | 59.152 | 34.018 | 24.215 | 21.258 | 35.243 | 21.946 | 17.4 | 18.68 |
| Selling & Marketing Expenses
| 29.645 | 52.483 | 52.088 | 63.927 | 289.573 | 339.402 | 258.743 | 245.186 | 146.819 | 101.275 | 81.557 | 51.895 | 81.648 | 130.645 | 71.715 |
| SG&A
| 122.943 | 126.008 | 117.737 | 145.888 | 349.267 | 423.91 | 332.705 | 304.338 | 180.837 | 125.491 | 102.815 | 87.138 | 103.594 | 148.045 | 90.396 |
| Other Expenses
| -59.406 | 853.757 | 335.065 | 272.372 | 301.123 | 1.737 | 0.287 | 30.708 | 63.532 | 0.713 | 0.151 | 5.56 | 0.048 | 7.387 | 2.221 |
| Operating Expenses
| 459.064 | 1,047.699 | 486.116 | 457.936 | 688.69 | 686.47 | 556.836 | 472.972 | 303.305 | 223.103 | 189.147 | 182.97 | 207.746 | 195.817 | 133.032 |
| Operating Income
| 1,541.792 | 4,481.157 | 3,595.912 | 92.007 | 582.663 | 413.956 | 595.797 | 339.008 | 218.748 | 678.727 | 70.335 | 384.218 | 484.954 | 192.895 | 46.538 |
| Operating Income Ratio
| 0.175 | 0.344 | 0.364 | 0.017 | 0.098 | 0.069 | 0.126 | 0.098 | 0.076 | 0.311 | 0.044 | 0.221 | 0.255 | 0.135 | 0.055 |
| Total Other Income Expenses Net
| -5.827 | -2.595 | -17.531 | -424.684 | 1.09 | 1.737 | -16.142 | 22.897 | 63.526 | 0.713 | 0.151 | -74.669 | -111.561 | -52.147 | -16.257 |
| Income Before Tax
| 1,535.966 | 4,478.562 | 3,583.216 | 15.809 | 583.753 | 415.693 | 596.085 | 369.595 | 282.274 | 679.439 | 70.486 | 389.778 | 484.951 | 199.131 | 48.758 |
| Income Before Tax Ratio
| 0.174 | 0.343 | 0.363 | 0.003 | 0.098 | 0.069 | 0.126 | 0.107 | 0.099 | 0.311 | 0.044 | 0.224 | 0.255 | 0.139 | 0.058 |
| Income Tax Expense
| 257.266 | 668.323 | 551.879 | 12.9 | 77.142 | 117.488 | 90.893 | 48.128 | 43.542 | 7.676 | 6.057 | 54.885 | 118.675 | 28.425 | 5.535 |
| Net Income
| 1,283.244 | 3,806.809 | 3,018.471 | 2.91 | 516.854 | 363.087 | 517.54 | 317.811 | 239.866 | 671.763 | 64.437 | 334.894 | 366.276 | 172.798 | 44.156 |
| Net Income Ratio
| 0.145 | 0.292 | 0.306 | 0.001 | 0.087 | 0.06 | 0.109 | 0.092 | 0.084 | 0.307 | 0.04 | 0.193 | 0.193 | 0.121 | 0.052 |
| EPS
| 0.15 | 0.44 | 0.36 | 0 | 0.06 | 0.041 | 0.06 | 0.04 | 0.032 | 0.1 | 0.011 | 0.065 | 0.09 | 0.044 | 0.011 |
| EPS Diluted
| 0.15 | 0.44 | 0.36 | 0 | 0.06 | 0.04 | 0.06 | 0.04 | 0.032 | 0.1 | 0.011 | 0.065 | 0.09 | 0.044 | 0.011 |
| EBITDA
| 2,517.073 | 5,441.741 | 4,300.132 | 743.693 | 1,276.392 | 1,049.127 | 1,175.355 | 859.084 | 690.682 | 1,057.588 | 350.103 | 677.285 | 801.39 | 424.901 | 145.188 |
| EBITDA Ratio
| 0.285 | 0.417 | 0.436 | 0.141 | 0.214 | 0.175 | 0.248 | 0.248 | 0.241 | 0.484 | 0.218 | 0.39 | 0.422 | 0.297 | 0.172 |